What research abstracts presented at this year’s American Society of Clinical Oncology annual meeting will have the biggest potential impact on clinical practice? Cleveland Clinic Cancer Center physicians make their picks.
PD-L2 plays a significant part in prostate cancer immune modulation and could be a worthwhile prognostic biomarker as well as an immune checkpoint inhibition target, according to a large genetic analysis.
The IsoPSA prostate-specific antigen test could reduce unnecessary prostate biopsies by more than 40% while reliably differentiating among high-grade, low-grade and benign disease, a new validation study has found.
Active surveillance is a viable choice for African-American prostate cancer patients with low- or intermediate-risk disease, enabling long treatment-free periods and reasonable post-treatment outcomes, new Cleveland Clinic research shows.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
A new study shows that advanced urologic oncology training significantly increases a urologist’s likelihood of detecting prostate cancer via biopsy.
Data from nearly 2,000 patients showed that certain adverse pathological features were more common in men with very high-risk prostate cancer.
Innovative diagnostic tools and treatments are refining management of prostate cancer, and helping clinicians and patients make better decisions.
Prostate cancer patients treated with moderately hypofractionated IMRT show good tumor control and low toxicity even 10 years later.
Cleveland Clinic researchers conducted a retrospective study to determine whether NGS-based testing results alter clinical treat-ment decisions and ultimately if such changes or interventions can prolong survival in mCRPC patients.
The paradigm for prostate cancer screening with PSA continues to evolve, as do complementary testing tools. Here’s one take from a longtime urologist.